How did AbbVie outperform the S&P 500?

AbbVie outperformed by 139 percentage points, with the S&P 500 returning 261% versus AbbVie's 400%.

What were Humira's sales in Q1 2026?

Humira sales were $688 million in Q1 2026.

How did AbbVie achieve this performance despite Humira's decline?

AbbVie offset Humira's decline by diversifying its drug portfolio, particularly in immunology and oncology, along with a strong pipeline of new drugs.

AbbVie Delivers 400% Returns, Beating S&P 500 by 139%

AbbVie (ABBV) has delivered a remarkable 400% return over the past decade, beating the S&P 500's 261% return by 139 percentage points. This performance came despite the sharp decline in Humira sales due to biosimilar competition.

By: Wrqti Editorial

June 3, 2026

2 min read

Source: 24/7 Wall St.

Key Numbers

ten year return

400%

s&p 500 return

261%

excess return

139%

humira q1 2026 sales

$688 million

AbbVie (NYSE:ABBV) has achieved an extraordinary 400% return over the past ten years, outperforming the S&P 500's 261% return by 139 percentage points. This impressive feat occurred despite the significant challenges posed by the patent expiration of its blockbuster drug, Humira.

Details

AbbVie was heavily reliant on Humira, the world's best-selling drug, which generated massive cash flows. However, after its U.S. patent expired in 2023, biosimilars eroded its sales dramatically. In Q1 2026, Humira sales plummeted to just $688 million, down from peak annual sales exceeding $5 billion.

Context

Despite Humira's decline, AbbVie managed to offset the loss through its diversified portfolio, particularly in immunology and oncology. The company's strategic focus on new drugs and pipeline development helped sustain earnings growth and investor confidence. Forward-looking prospects remain positive due to a robust pipeline.

What This Means for Investors

AbbVie's performance demonstrates its ability to adapt to market changes even after losing a key product. For investors, this signals strong management and diversification strategy, though long-term success will depend on how well new drugs compensate for Humira's decline.

Frequently Asked Questions

AbbVie achieved a cumulative return of 400% over the past ten years.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.